HFHiva Fassihi

Hiva Fassihi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hiva Fassihi has a total of 129 co-authors. Here are the top co-authors by number of shared publications:

  • Alan Robert Lehmann

    UK National Xeroderma Pigmentosum Service, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust London United Kingdom

    4 shared publications
  • Paola Giunti

    Ataxia Centre, Queen Square Institute of Neurology, Department of Molecular and Movement Neurosciences, University College London, United Kingdom

    2 shared publications
  • Adam Fityan

    Dermatology Department University Hospital, Southampton NHS Foundation Trust Southampton UK

    1 shared publication
  • Adesoji Abiona

    UK National Xeroderma Pigmentosum Service, Guy’s and St Thomas’ NHS Foundation Trust , London SE1 7EH , UK

    1 shared publication
  • Alain Sarasin

    CNRS UMR9019 Genome Integrity and Cancers, Institut Gustave Roussy, Universite Paris-Saclay, Villejuif, France

    1 shared publication
  • Alan Lehmann

    National Xeroderma Pigmentosum Service, Department of Photodermatology, St John’s Institute of Dermatology, Guy’s and St Thomas’ Foundation Trust, London, UK

    1 shared publication

Latest Publications

  • Open Access

    Determinants of real-world sunscreen effectiveness: from ultraviolet radiation photobiology to human behaviour

    by Mona Panahi, Ryan I Sia, Xinyi Du-Harpur, Hiva Fassihi

    Sunscreen is often presented as a straightforward intervention for reducing sun-induced skin damage. However, in practice its effectiveness is determined by a broad network of interacting factors rather than labelled sun protection factor (SPF) alone. Real-world protection depends not only on filter chemistry and test performance but also on wavelength coverage, formulation, durability, regulatory standards, user behaviour and public understanding. At the same time, sunscreen has become an increasingly contested topic, shaped by debates regarding systemic absorption, environmental impact, misinformation and the limitations of uniform public health messaging. This review examines the determinants of sunscreen effectiveness in the real world. Firstly, the photobiological basis of photoprotection is considered, including the differing contributions of UVB, UVA and, in selected contexts, visible light to skin damage. Secondly, the ways in which sunscreen efficacy is measured and regulated are reviewed, with particular attention to the limitations of SPF as a sole marker of protection. Thirdly, current evidence relating to human and environmental implications of sunscreen use is assessed. Finally, behavioural, social and communicative factors that influence real-world use are explored, together with emerging personalized and technological approaches to photoprotection. Overall, the evidence suggests that sunscreen effectiveness is best understood not as a fixed property of the product alone, but as the outcome of an interaction between photobiology, formulation science, regulation and human behaviour. This broader framework helps explain why scientifically efficacious products may deliver suboptimal protection in practice, and why future improvements in photoprotection will depend not only on innovation in formulations but also on clearer, more risk-stratified guidance that supports consistent use in everyday life.

  • Open Access

    Central Nervous System Tumors in Xeroderma Pigmentosum: Five Cases and Review of the Literature

    by Farrah S. Bakr, Huseyin Arisoy, Alan R. Lehmann, Paola Giunti, Hiva Fassihi

    Background: Xeroderma pigmentosum (XP) is a rare autosomal recessive DNA‐repair disorder characterized by extreme ultraviolet radiation (UVR) sensitivity, markedly increased cutaneous malignancy risk, and progressive neurological disease in approximately one‐third of patients. Emerging evidence suggests an increased risk of internal malignancies, particularly primary central nervous system (CNS) tumors. Objective: The aim of this work was to describe primary CNS tumors in patients with XP managed at the UK National XP Service and to review the literature. Methods: We retrospectively identified five genetically confirmed XP patients with primary CNS tumors followed longitudinally within the multidisciplinary UK National XP Service, including regular neurological evaluation. Results: Five patients (aged 20–79 years) developed primary CNS tumors: three XP‐C and two XP‐A. Tumors included gliomas, meningiomas, and subependymoma. CNS tumors occurred predominantly in younger patients with XP‐C, whereas late‐onset, slow‐growing meningiomas were observed in milder XP‐A phenotypes. One patient with XP‐C died of glioblastoma. Conclusions: XP is associated with primary CNS tumor risk, particularly in XP‐C and late‐onset XP‐A, supporting regular neurological assessment and targeted neuroimaging. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

  • Open Access

    Unusual Disease‐Progression in Two Siblings With Xeroderma Pigmentosum Group G

    by Elena Botta, Heather Fawcett, Donata Orioli, Hiva Fassihi, Alan R. Lehmann

    Protein truncation mutations in the gene for XPG nuclease cause a very severe clinical phenotype. Two siblings have splicing mutations, which result in in-frame deletions and a less severe phenotype.

  • Skin Cancer Induction by the Antimycotic Drug Voriconazole Is Caused by Impaired DNA Damage Detection Due to Chromatin Compaction

    by Sara Giovannini, Lisa Weibel, Birgit Schittek, Tobias Sinnberg, Martin Schaller, Christina Lemberg, Birgit Fehrenbacher, Antje Biesemeier, Renate Nordin, Irina Ivanova, et al.


  • A novel variant in PTPN11, c.1277A>G p.(His426Arg), in a patient with Noonan syndrome with multiple lentigines

    by Olivia Kuo, Kevin Molloy, Ataf Sabir, Andrew Fleming, Matthew Edwards, Deborah Morris-Rosendahl, Hiva Fassihi, Philip Preston

    Noonan syndrome with multiple lentigines (NSML) is a rare autosomal dominant condition arising from gene variants involved in the RAS-MAPK pathway. The presence of multiple skin cancers is not widely reported in NSML. We report on a novel missense variant causing NSML in a patient with an unusual distribution of lentigines and multiple skin cancers. An increased awareness of the potential for malignant change of lentigines in NSML may encourage regular skin surveillance as a mainstay of multidisciplinary management, enabling early diagnosis and management of skin cancers in this group of patients.

  • Open Access

    Neurological disease in xeroderma pigmentosum: prospective cohort study of its features and progression

    by Hector Garcia-Moreno, Douglas R Langbehn, Adesoji Abiona, Isabel Garrood, Zofia Fleszar, Marta Antonia Manes, Ana M Susana Morley, Emma Craythorne, Shehla Mohammed, Tanya Henshaw, et al.

    Xeroderma pigmentosum (XP) results from biallelic mutations in any of eight genes involved in DNA repair systems, thus defining eight different genotypes (XPA, XPB, XPC, XPD, XPE, XPF, XPG and XP variant or XPV). In addition to cutaneous and ophthalmological features, some patients present with XP neurological disease. It is unknown whether the different neurological signs and their progression differ among groups. Therefore, we aim to characterize the XP neurological disease and its evolution in the heterogeneous UK XP cohort. Patients with XP were followed in the UK National XP Service, from 2009 to 2021. Age of onset for different events was recorded. Cerebellar ataxia and additional neurological signs and symptoms were rated with the Scale for the Assessment and Rating of Ataxia (SARA), the Inventory of Non-Ataxia Signs (INAS) and the Activities of Daily Living questionnaire (ADL). Patients’ mutations received scores based on their predicted effects. Data from available ancillary tests were collected. Ninety-three XP patients were recruited. Thirty-six (38.7%) reported neurological symptoms, especially in the XPA, XPD and XPG groups, with early-onset and late-onset forms, and typically appearing after cutaneous and ophthalmological symptoms. XPA, XPD and XPG patients showed higher SARA scores compared to XPC, XPE and XPV. SARA total scores significantly increased over time in XPD (0.91 points/year, 95% confidence interval: 0.61, 1.21) and XPA (0.63 points/year, 95% confidence interval: 0.38, 0.89). Hyporeflexia, hypopallesthaesia, upper motor neuron signs, chorea, dystonia, oculomotor signs and cognitive impairment were frequent findings in XPA, XPD and XPG. Cerebellar and global brain atrophy, axonal sensory and sensorimotor neuropathies, and sensorineural hearing loss were common findings in patients. Some XPC, XPE and XPV cases presented with abnormalities on examination and/or ancillary tests, suggesting underlying neurological involvement. More severe mutations were associated with a faster progression in SARA total score in XPA (0.40 points/year per 1-unit increase in severity score) and XPD (0.60 points/year per 1-unit increase), and in ADL total score in XPA (0.35 points/year per 1-unit increase). Symptomatic and asymptomatic forms of neurological disease are frequent in XP patients, and neurological symptoms can be an important cause of disability. Typically, the neurological disease will be preceded by cutaneous and ophthalmological features, and these should be actively searched in patients with idiopathic late-onset neurological syndromes. Scales assessing cerebellar function, especially walking and speech, and disability can show progression in some of the groups. Mutation severity can be used as a prognostic biomarker for stratification purposes in clinical trials.


  • Open Access

    Genomic mutation landscape of skin cancers from DNA repair-deficient xeroderma pigmentosum patients

    by Andrey A. Yurchenko, Fatemeh Rajabi, Tirzah Braz-Petta, Hiva Fassihi, Alan Lehmann, Chikako Nishigori, Jinxin Wang, Ismael Padioleau, Konstantin Gunbin, Leonardo Panunzi, et al.

    Xeroderma pigmentosum (XP) is a genetic disorder caused by mutations in genes of the Nucleotide Excision Repair (NER) pathway (groups A-G) or in Translesion Synthesis DNA polymerase η (V). XP is associated with an increased skin cancer risk, reaching, for some groups, several thousand-fold compared to the general population. Here, we analyze 38 skin cancer genomes from five XP groups. We find that the activity of NER determines heterogeneity of the mutation rates across skin cancer genomes and that transcription-coupled NER extends beyond the gene boundaries reducing the intergenic mutation rate. Mutational profile in XP-V tumors and experiments with POLH knockout cell line reveal the role of polymerase η in the error-free bypass of (i) rare TpG and TpA DNA lesions, (ii) 3’ nucleotides in pyrimidine dimers, and (iii) TpT photodimers. Our study unravels the genetic basis of skin cancer risk in XP and provides insights into the mechanisms reducing UV-induced mutagenesis in the general population.


  • British Association of Dermatologists and British Photodermatology Group guidelines for narrowband ultraviolet B phototherapy 2022

    by Victoria Goulden, Tsui C. Ling, Parastoo Babakinejad, Robert Dawe, Ewan Eadie, Hiva Fassihi, Adam Fityan, Trish Garibaldinos, Sally H. Ibbotson, Ljuba Novakovic, et al.

    Linked Comment: P. Wolf. Br J Dermatol 2022; 187:285–286.


  • Open Access

    Bilateral cochlear implantation in a young patient with xeroderma pigmentosum (XP-D) and progressive sensorineural hearing loss—How to do it?

    by H Woodun, R Vetrivel Vedachalam, H Fassihi, P Achar

    Xeroderma pigmentosum (XP), a rare genetic skin condition, causes ultraviolet (UV)-induced neoplasms and possible neurological deficits including sensorineural hearingloss. We present the first case in literature of bilateral cochlear implantation (CI) in a patient with XP-D with neurodegeneration. Multi-disciplinary team members (national XP team, dermatologist, anaesthetist, theatre team, biophysicists) were involved. UV exposure from equipment and areas where the 14-year-old patient would track was measured. Maximum possible surgery was performed under operating headlights to limit higher-UV microscope exposure. Its bulb light intensity was reduced to achieve safe UV level (0–10 μW/cm2). Skin was protected under surgical drapes. Challenges included drilling unpredicted hard thick bone under low-intensity light and requiring bulkier Nucleus®-7 processor due to unanticipated increased scarring. A delayed left facial weakness was resolved with steroids. He is undergoing hearing rehabilitation. This highlights challenges of CI in XP. Its impact in preserving cognition and on neurodegeneration should also be observed.

  • Contributors

    by Eric Lim, Ziad Ali, Kevin Varty, John Wallwork, Philip Poole-Wilson, Mitra Shahidi, Michael Polkey, Peter Goldstraw, Jeevendra Kanagalingam, Azhar Shaida, et al.